EP4743089A1 - A3-ADENOSIN RECEPTOR LIGANDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH OCRL GENE DISFUNCTION - Google Patents

A3-ADENOSIN RECEPTOR LIGANDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH OCRL GENE DISFUNCTION

Info

Publication number
EP4743089A1
EP4743089A1 EP24739137.8A EP24739137A EP4743089A1 EP 4743089 A1 EP4743089 A1 EP 4743089A1 EP 24739137 A EP24739137 A EP 24739137A EP 4743089 A1 EP4743089 A1 EP 4743089A1
Authority
EP
European Patent Office
Prior art keywords
ocrl
disfunction
gene
treatment
diseases associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24739137.8A
Other languages
German (de)
French (fr)
Inventor
Matteis Maria Antonietta De
Leopoldo Staiano
Mariella Vicinanza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consiglio Nazionale delle Richerche CNR
Fondazione Telethon
Original Assignee
Consiglio Nazionale delle Richerche CNR
Fondazione Telethon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale delle Richerche CNR, Fondazione Telethon filed Critical Consiglio Nazionale delle Richerche CNR
Publication of EP4743089A1 publication Critical patent/EP4743089A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP24739137.8A 2023-07-10 2024-07-01 A3-ADENOSIN RECEPTOR LIGANDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH OCRL GENE DISFUNCTION Pending EP4743089A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102023000014340A IT202300014340A1 (en) 2023-07-10 2023-07-10 TREATMENT OF DISEASES ASSOCIATED WITH OCRL GENE DYSFUNCTION.
PCT/EP2024/068446 WO2025011999A1 (en) 2023-07-10 2024-07-01 A3 adenosine receptor ligands for use in the treatment of diseases associated with ocrl gene disfunction

Publications (1)

Publication Number Publication Date
EP4743089A1 true EP4743089A1 (en) 2026-05-20

Family

ID=88505296

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24739137.8A Pending EP4743089A1 (en) 2023-07-10 2024-07-01 A3-ADENOSIN RECEPTOR LIGANDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH OCRL GENE DISFUNCTION

Country Status (7)

Country Link
EP (1) EP4743089A1 (en)
KR (1) KR20260040431A (en)
CN (1) CN121666237A (en)
AU (1) AU2024288672A1 (en)
IL (1) IL325283A (en)
IT (1) IT202300014340A1 (en)
WO (1) WO2025011999A1 (en)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
EP0708781B1 (en) 1993-07-13 2001-10-04 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services A 3 adenosine receptor agonists
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
AU1399297A (en) 1996-01-24 1997-08-20 Sumitomo Chemical Company, Limited Dihalopropene compounds, their use as insecticides/acaricides and intermediates for their production
US6048865A (en) 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
JP2003517423A (en) 1997-07-29 2003-05-27 メドコ リサーチ、インコーポレイテッド N6-substituted adenosine-5'-uronamide as adenosine receptor modulator
WO1999020284A1 (en) 1997-10-23 1999-04-29 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid a and adenosine receptor agents
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
EP1983990B1 (en) 2006-01-26 2011-03-23 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services A3 adenosine receptor allosteric modulators
WO2010020981A1 (en) * 2008-08-19 2010-02-25 Universiteit Leiden A3 adenosine receptor allosteric modulators
ES2578363B1 (en) * 2015-01-22 2017-01-31 Palobiofarma, S.L. A3 adenosine receptor modulators
CA2980431A1 (en) * 2017-09-27 2019-03-27 Sebastien Carreno Compounds for use in the treatment or prevention of lowe syndrome or dent disease, and methods therefor
IL264112A (en) * 2019-01-06 2020-07-30 Fishman Pnina Adenosine a3 receptor ligand for use in lowering adipocyte levels

Also Published As

Publication number Publication date
CN121666237A (en) 2026-03-13
KR20260040431A (en) 2026-03-24
IT202300014340A1 (en) 2025-01-10
AU2024288672A1 (en) 2026-01-22
IL325283A (en) 2026-02-01
WO2025011999A1 (en) 2025-01-16

Similar Documents

Publication Publication Date Title
Choi et al. ORAI1 activates proliferation of lymphatic endothelial cells in response to laminar flow through Krüppel-like factors 2 and 4
Huang et al. CircRNA–miRNA networks in regulating bone disease
MX2023008504A (en) Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf.
EP3811946A4 (en) USE OF A CDK4/6 INHIBITOR IN COMBINATION WITH AN EGFR INHIBITOR IN THE MANUFACTURE OF A DRUG FOR THE TREATMENT OF TUMOR DISEASES
EP4121047C0 (en) IMIDAZOLYLTHIOPENSULFONYLCARBAMATES FOR USE IN THE TREATMENT OF ANGIOTENSIN II-RELATED DISEASES
EP4105214A4 (en) USE OF JAK INHIBITORS IN THE MANUFACTURING OF DRUGS FOR TREATING JAK KINASE RELATED DISEASES
EP4400105A4 (en) MEDICINE FOR THE PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH ANTI-OBESITY ACTIVITY
van der Wijk et al. TNFα-induced disruption of the blood–retinal barrier in vitro is regulated by intracellular 3′, 5′-cyclic adenosine monophosphate levels
DK3840753T3 (en) MIGALASTAT FOR USE IN METHODS OF TREATING FABRY'S DISEASE IN PATIENTS CARRYING A MUTATION IN THE GLA GENE
Liu et al. Zeb1 represses Mitf and regulates pigment synthesis, cell proliferation, and epithelial morphology
Zhang et al. Endothelial-specific YY1 governs sprouting angiogenesis through directly interacting with RBPJ
EP4444310A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH
Haefliger et al. Targeting Cx40 (Connexin40) expression or function reduces angiogenesis in the developing mouse retina
EP4469086A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH
EP4441225A4 (en) TREATMENT OF NEUROLOGICAL DISEASES WITH MODULATORS OF UNC13A GEN TRANSCRIPTS
EP4074828A4 (en) USE OF CYP4V2 AND RDCVF FOR PRODUCING MEDICINAL PRODUCTS
MX2022005414A (en) ADRAC2 ADRENORECEPTOR INHIBITORS.
Dotterweich et al. Mesenchymal stem cell contact promotes CCN1 splicing and transcription in myeloma cells
Rothuizen et al. Promoting tropoelastin expression in arterial and venous vascular smooth muscle cells and fibroblasts for vascular tissue engineering
EP4352265A4 (en) USE OF CANCER CELL EXPRESSION OF CADHERIN 12 AND CADHERIN 18 FOR THE TREATMENT OF BLADDER CANCER
Uhrin Cellular and molecular mechanisms of vasculogenesis, angiogenesis, and lymphangiogenesis
EP4743098A1 (en) THERAPEUTIC USE OF FIBROBLASTS IN THE TREATMENT OF PSORIASIS
EP3891307C0 (en) METHOD FOR DETERMINING A PATIENT'S RESPONSE TO INTERFERON TYPE I TREATMENT AND USE OF INTERFERON TYPE I TO TREAT A PATIENT WITH SPECIFIED SINGLE NUCLEOTIDE POLYMORPHISM
Bautch et al. The beauty and complexity of blood vessel patterning
EP4419671A4 (en) GENE THERAPY FOR THE TREATMENT OF WILSON DISEASE

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE